Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Malignant Neoplasm × Imatinib Mesylate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 55 Leukemia 31 Gastrointestinal Stromal Tumors 26 Leukemia, Myeloid, Chronic-Phase 21 Precursor Cell Lymphoblastic Leukemia-Lymphoma 19 Philadelphia Chromosome 8 Neoplasm Metastasis 8 Melanoma 8 Lung Neoplasms 8 Blast Crisis 8 Brain Neoplasms 7 Neoplasms 5 Glioblastoma 5 Carcinoma, Non-Small-Cell Lung 5 Small Cell Lung Carcinoma 4 Recurrence 4 Prostatic Neoplasms 4 Primary Myelofibrosis 4 Polycythemia Vera 4 Ovarian Neoplasms 4 Leukemia, Myelomonocytic, Chronic 4 Leukemia, Myeloid, Acute 4 Leukemia, Myeloid, Accelerated Phase 4 Leukemia, Myeloid 4 Dermatofibrosarcoma 4 Sarcoma 3 Osteosarcoma 3 Meningioma 3 Head and Neck Neoplasms 3 Gliosarcoma 3

Interventions

trametinib 1 dabrafenib 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡